Amgen resolves G-CSF patent litigation with Teva
Israeli firm admits Neutroval infringes Amgen patents
The US District Court in Pennsylvania has prohibited Israeli generics manufacturer Teva Pharmaceuticals from infringing Amgen's patents relating to human G-CSF (granulocyte colony-stimulating factor) and methods for its use.
Teva admitted that its Neutroval product infringes two Amgen patents, US Patent Nos. 5,580,755 and 5,582,823, and that those patents are valid and enforceable. The Court's injunction extends until November 2013, after which Teva may sell Neutroval in the US.
Teva has also agreed not to sell Neugranin, another Teva G-CSF product, until 2013 unless it obtains a final court decision that Neugranin does not infringe Amgen's patents.
The two patents at issue expire in December 2013.
The settlement terms do not include any financial payments between Teva and Amgen.
‘We are very pleased with this outcome, as it reaffirms the validity of these important patents,’ said David Scott, senior vice president, general counsel and secretary at Amgen, a developer of human therapeutics based in California, US.
‘This closes this matter and allows Amgen to continue to focus on bringing innovative therapies to patients.’
